Radinitinib should be Ranitidine, an H2 receptor blocker, the main mechanism of action is to inhibit the secretion of gastric acid to further control gastric and duodenal diseases. Efficacy and effects: 1. peptic ulcer bleeding, diffuse gastric mucosal lesion bleeding, anastomotic ulcer bleeding, prevention of bleeding after gastric surgery. 2. It is used for the treatment of acute gastric mucosal bleeding that occurs under stress and after the application of aspirin; it is used for the prevention of ulcer hemorrhage that is likely to occur under stress. 3. To prevent gastroesophageal reflux in patients under general anesthesia, after major surgery, and in comatose patients, resulting in aspiration pneumonia. Adverse Reactions: Rash, gastrointestinal disorders, abnormal liver function, granulocytopenia, headache, dizziness, abnormal taste may occur after use. Children under 8 years of age, pregnancy and lactation is prohibited; severe renal function abnormalities should be used with caution; allergic to the product is prohibited. After the use of the drug appeared obvious abdominal pain, headache, as well as the whole body multiple rashes, etc., to stop using the drug in time, seek medical attention and observation. The drug should be used under the guidance of a doctor, do not use the drug blindly.